{"title":"Ofatumumab for the treatment of relapsing‐remitting MS","authors":"S. Chaplin","doi":"10.1002/psb.1987","DOIUrl":null,"url":null,"abstract":"Ofatumumab (Kesimpta) is a new anti‐CD20 monoclonal antibody therapy for the treatment of relapsing‐remitting multiple sclerosis. This article outlines its properties, efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.1987","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Ofatumumab (Kesimpta) is a new anti‐CD20 monoclonal antibody therapy for the treatment of relapsing‐remitting multiple sclerosis. This article outlines its properties, efficacy and adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
